BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 33607608)

  • 1. Short-acting intramuscular second-generation antipsychotic drugs for acutely agitated patients with schizophrenia spectrum disorders. A systematic review and network meta-analysis.
    Paris G; Bighelli I; Deste G; Siafis S; Schneider-Thoma J; Zhu Y; Davis JM; Vita A; Leucht S
    Schizophr Res; 2021 Mar; 229():3-11. PubMed ID: 33607608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
    Breier A; Meehan K; Birkett M; David S; Ferchland I; Sutton V; Taylor CC; Palmer R; Dossenbach M; Kiesler G; Brook S; Wright P
    Arch Gen Psychiatry; 2002 May; 59(5):441-8. PubMed ID: 11982448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia.
    Battaglia J; Houston JP; Ahl J; Meyers AL; Kaiser CJ
    Clin Ther; 2005 Oct; 27(10):1612-8. PubMed ID: 16330297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
    Andrezina R; Josiassen RC; Marcus RN; Oren DA; Manos G; Stock E; Carson WH; Iwamoto T
    Psychopharmacology (Berl); 2006 Oct; 188(3):281-92. PubMed ID: 16953381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients.
    Lindborg SR; Beasley CM; Alaka K; Taylor CC
    Psychiatry Res; 2003 Jul; 119(1-2):113-23. PubMed ID: 12860365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation.
    Castle DJ; Udristoiu T; Kim CY; Sarosi A; Pidrman V; Omar AN; Rosales JI; Melamed Y; Isik T; Karagianis J; Treuer T
    World J Biol Psychiatry; 2009; 10(1):43-53. PubMed ID: 19137460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior.
    Chan HY; Ree SC; Su LW; Chen JJ; Chou SY; Chen CK; Chen YS
    J Clin Psychopharmacol; 2014 Jun; 34(3):355-8. PubMed ID: 24743717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial.
    Huang CL; Hwang TJ; Chen YH; Huang GH; Hsieh MH; Chen HH; Hwu HG
    J Formos Med Assoc; 2015 May; 114(5):438-45. PubMed ID: 25791540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia.
    Suzuki H; Gen K; Takahashi Y
    Hum Psychopharmacol; 2014 Jan; 29(1):83-8. PubMed ID: 24424709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of intramuscular ziprasidone in the management of acute psychotic agitation.
    Mendelowitz AJ
    Ann Clin Psychiatry; 2004; 16(3):145-54. PubMed ID: 15517847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New formulations of olanzapine in the treatment of acute agitation].
    Bartkó G
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):171-8. PubMed ID: 17211052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses.
    Zhu Y; Krause M; Huhn M; Rothe P; Schneider-Thoma J; Chaimani A; Li C; Davis JM; Leucht S
    Lancet Psychiatry; 2017 Sep; 4(9):694-705. PubMed ID: 28736102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy.
    Wright P; Meehan K; Birkett M; Lindborg SR; Taylor CC; Morris P; Breier A
    Clin Ther; 2003 May; 25(5):1420-8. PubMed ID: 12867218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation.
    Katagiri H; Fujikoshi S; Suzuki T; Fujita K; Sugiyama N; Takahashi M; Gomez JC
    BMC Psychiatry; 2013 Jan; 13():20. PubMed ID: 23311957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety.
    Citrome L
    J Clin Psychiatry; 2007 Dec; 68(12):1876-85. PubMed ID: 18162018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparative efficacy of intramuscular antipsychotics for the management of acute agitation.
    Bosanac P; Hollander Y; Castle D
    Australas Psychiatry; 2013 Dec; 21(6):554-62. PubMed ID: 23996795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation.
    MacDonald K; Wilson M; Minassian A; Vilke GM; Becker O; Tallian K; Cobb P; Perez R; Galangue B; Feifel D
    J Clin Psychopharmacol; 2012 Jun; 32(3):317-22. PubMed ID: 22544013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
    Samara MT; Dold M; Gianatsi M; Nikolakopoulou A; Helfer B; Salanti G; Leucht S
    JAMA Psychiatry; 2016 Mar; 73(3):199-210. PubMed ID: 26842482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.